Market revenue in 2023 | USD 258.7 million |
Market revenue in 2030 | USD 426.5 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Product registration & clinical trial applications |
Fastest growing segment | Legal representation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory consulting, Legal representation, Regulatory writing & publishing, Product registration & clinical trial applications, Regulatory Submissions, Regulatory Operations, Other services |
Key market players worldwide | Genpact Ltd, Criterium Inc., Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, Labcorp Drug Development, FREYR Battery Inc, Cencora Inc, Pharmexon, QVigilance, BlueReg Group, ZEINCRO Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs outsourcing market will help companies and investors design strategic landscapes.
Product registration & clinical trial applications was the largest segment with a revenue share of 25.94% in 2023. Horizon Databook has segmented the UK regulatory affairs outsourcing market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, regulatory submissions, regulatory operations, other services covering the revenue growth of each sub-segment from 2018 to 2030.
The UK accounts for 10.0% of global pharmaceutical R&D and stands third globally, after the U.S. and Japan. The demand for generic products has also grown considerably owing to government support for generics over branded drugs.
This trend is attracting various small- and mid-size biopharmaceuticals and medical device companies to enter the UK, thereby increasing the demand for regulatory support services. Thus, due to lack of expertise and financial aid, these companies cannot establish their own regulatory department.
In addition, a significant impact of Brexit on the regulatory environment of the UK is expected as it may lead to the relocation of the headquarters of EMA to another country. This will in turn negatively impact the availability of top regulatory agents in the country and ultimately make the UK a less attractive market for established and emerging biopharmaceutical and medical device companies.
Horizon Databook provides a detailed overview of country-level data and insights on the UK regulatory affairs outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into UK regulatory affairs outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account